GeneDx Faces Class Action Lawsuit Over Alleged Securities Violations

The complaint alleges that GeneDx violated the Securities Exchange Act of 1934 by providing false information to the market. The core of the dispute involves a significant decline in adjusted gross margins during the first quarter of 2026, which forced the company to lower its full-year earnings projections. According to the litigation, these financial setbacks contradict the positive outlook previously presented to shareholders during the specified class period.

Shareholders who incurred losses have until August 3, 2026, to contact the DJS Law Group regarding potential lead plaintiff appointments. While participation in the recovery process does not strictly require this designation, the firm is currently organizing the case to address claims arising from the company's market disclosures. David J. Schwartz of the DJS Law Group is handling inquiries for those seeking to participate in the recovery efforts.